Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome
SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in a poster presentation at ObesityWeek® 2025, the annual meeting of The Obesity Society. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic disorders. Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials.
Results of an exploratory analysis of data from the company's Phase 2 VENTURE clinical trial of VK2735 dosed as a weekly subcutaneous injection were presented in a poster session on Thursday afternoon. The exploratory analysis evaluated the impact of VK2735 treatment on the prevalence of prediabetes and metabolic syndrome (MetS) following the 13-week study. Treatment with VK2735 was shown to improve cardiometabolic parameters in patients, including reductions in the prevalence of prediabetes and MetS at the end of the 13-week treatment period.
Data from the study showed that 78% of VK2735-treated patients who were characterized as prediabetic at baseline had successfully shifted to normal glycemic status at Week 13, as compared to 29% for placebo patients (p=0.0008).
Shift in Diabetes Status from Baseline to Week 13
|
Parameter1 |
Placebo |
VK2735 2.5 mg |
VK2735 5 mg |
VK2735 10 mg |
VK2735 15 mg |
Combined VK2735 Arms |
|
Prediabetic at baseline2 |
14 |
21 |
21 |
16 |
16 |
74 |
|
Number shifting to normoglycemic at Week 133(%) |
4 (29 %) |
17 (81 %) |
16 (76 %) |
10 (63 %) |
15 (94 %) |
58 (78 %) |
|
p-value vs. placebo4 |
- |
0.0036 |
0.0078 |
0.0697 |
0.0023 |
0.0008 |
|
Notes: 1) Observed values, no imputation for missing data. 2) Defined as patients with fasting plasma glucose 100 mg/dL to 125 mg/dL or HbA1c 5.7% to 6.4%. 3) Defined as fasting plasma glucose
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |